Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

We recently compiled a list of the 10 AI News You Should Not Miss. In this article, we are going to take a look at where ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma partnerships with Eli ...

The pharma giant is partnering with software firms to imagine new drugs, find targets, and design clinical trials ...

Among the most important aspects of this story is AlphaFold, the artificial intelligence and foundation model platform developed by Google DeepMind and Isomorphic Labs, both Alphabet companies.

Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this ...